IE45353B1 - A procress for preparing solid sodium amoxycillin - Google Patents

A procress for preparing solid sodium amoxycillin

Info

Publication number
IE45353B1
IE45353B1 IE1399/77A IE139977A IE45353B1 IE 45353 B1 IE45353 B1 IE 45353B1 IE 1399/77 A IE1399/77 A IE 1399/77A IE 139977 A IE139977 A IE 139977A IE 45353 B1 IE45353 B1 IE 45353B1
Authority
IE
Ireland
Prior art keywords
carbinol
amoxycillin
sodium amoxycillin
sodium
tert
Prior art date
Application number
IE1399/77A
Other versions
IE45353L (en
Original Assignee
Beecham Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB28179/76A external-priority patent/GB1527557A/en
Application filed by Beecham Group Ltd filed Critical Beecham Group Ltd
Publication of IE45353L publication Critical patent/IE45353L/en
Publication of IE45353B1 publication Critical patent/IE45353B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D499/04—Preparation
    • C07D499/14—Preparation of salts
    • C07D499/16—Preparation of salts of alkali or alkaline earth metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A process for the preparation of solid sodium amoxicillin, which consists of lyophilizing a solution of sodium amoxicillin in a solvent system containing water and at least one secondary or tertiary C4 or C5 carbinol, which has a water solubility at 25 ° C of 5 Minimum weight / volume.

Description

The present invention relates to an improved sodium amxycillin and to a process for its preparation.
Patent Specification No. 33574 discloses inter alia amoxycillin and salts thereof. Amoxycillin which is the penicillin of the formula (I): HO is widely recognised as having broad spectrum antibacterial activity of a high order. One of amoxycillin’s great advantages is that it is very well absorbed after oral administration but there are occasions when it is desirable to administer it parenterally. It is possible to use the methods disclosed in Patent Specification No. 33574 to form for example the sodium salt of amoxycillin which may then be dissolved in sterile water and used as an injectable composition. However, the previously disclosed process for the preparation of the sodium salt tends to produce a product which contains up to 10% of impurities. This disadvantage has not prevented use of the known sodium salt in forming injectable compositions of amoxycillin as the impurities have proved to be Sufficiently non-toxic. However, it would clearly be of advantage if a process could be found that was - 2 45353 able to provide a sodium amoxycillin which was of improved purity and which has good stability on storage. Such an improved sodium amoxycillin has now been prepared by a freeze drying process.
Accordingly the present invention provides a process for the preparation of a solid sodium amoxycillin which process comprises freeze drying a solution of sodium amoxycillin in a solved: system which contains water and a secondary or tertiary carbinol of 4 or 5 carbon atoms which is at least 5% w/v soluble in water at 25°C.the secondary or tertiary carbinol being present in the solvent system in concentration from 2% to 60% v/v (or to its maximum miscibility if lower).
The solvent system for use in the process of this invention IS will, normally contain from 4% to 50% v/v of a secondary or tertiary carbinol. More suitably the solvent system will contain from 8% v/v to *5% v/v of a secondary or tertiary carbinol and preferably 19% v/v to 25% v/v. If desired a mixture of secondary or tertiary carbinols may be employed but this is normally less acceptable than using a single such compound.
The solvent system may also contain small amounts of other pharmaceutically acceptable solvents such as primary carbinols but in general it is preferable that such solvents are not present.
Suitable secondary or tertiary carbinols include sec-butanol,tert-butanol, 2-pentanol, 5-pentanol, 2-methylbutan-2-ol.
Most suitably the carbinol used is a tertiary 5 carbinol.
The preferred carbinol for use in this invention is tert-butanol. Use of tert-butanol as part of the solvent system has been found to give considerable and hitherto unpredictable advantages especially in terms of ease of operation of the process, the high purity and toxicological acceptability of the product, the low resulting solvent residues and the freedom from particulate matter on redissolution.
The concentration of sodium amoxycillin present in solution immediately prior to freezing is suitably in the range S%w/v to 20% w/v, more suitably in the range 10% w/v to 15% w/v, for example, about 12% w/v.
The solution to be freeze dried may be prepared by any convenient method but it is believed that the most suitable method is by the addition of a solution of a sodium base to zwitterianic amoxycillin suspended in a mixture of water and a secondary or tertiary carbinol followed by any upward adjustment of volumes thought desirable, The amoxycillin used is preferably amoxycillin trihydrate and the base is preferably sodium hydroxide although trisodium phosphate is also envisaged. - 4 35353 Normally the solution of the sodium base is added slowly until a clear solution is obtained. Care should be taken that a large excess of base is not added. Generally between 1 and 1.2 equivalents of the sodium base is employed, for example about 1.1. equivalents.
It is preferable that the temperature of the solutions is kept below 25°C at all times to minimise decomposition. More suitably once addition of the base has begun the solutions are maintained at a temperature not substantially in excess of 20°.
Normally the solvents used have previously been rendered pyrogen free.
Once the solution of sodium amoxycillin has been prepared It should be cooled for use or for storage.
Most suitably the solution is cooled to about 0°C.
It is believed advisable to freeze dry the solution as soon as conveniently possible after it is prepared.
The freeze drying process may be carried out following standard procedures. The solution is frozen and the frozen material is subjected to low temperatures and pressures so that the solvent is removed without melting. In this present process, the frozen material is dried until a solid powder results containing not more than 10% by weight and preferably not more than 6% by weight of residual solvent.
The initial temperature at which evaporation is begun should be below -25°C most suitably below -50°C and preferably below -35°C. The pressure will generally be reduced to less than 0.2τ. 48353 The evaporation of solvents causes the solution to cool further, which slows the drying process. The evaporation may be accelerated by supplying heat and allowing the temperature of the frozen material to rise , gradually. The rate at which heat is supplied and the temperature of the solution is allowed to rise must be such, that the no melting occurs. The rate at which the solution is heated is dependent upon the rate at which the -—- solvent vapour is removed from above the frozen material.
If the solvent vapour pressure, (i.e. the quantity of vapour) increases too much, then melting occurs. Thus, the rate of heating depends upon factors such as the vacuum which may be pulled above the solid and the surface area from which the solvent may escape^ however, such factors are well known in the apt and suitable heating rates are generally, determined empirically. In the process of this invention, the final temperaturs at which drying is carried ί out does not normally exceed 60°C, and for preferance the final drying temperature is not greater than 50°C, Generally we prefer to carry out this drying over a period of from 1 to 3 days. - 6 45353 ιAn advantage of this process is that the solution to be freeze dried can be filled into open vials which are then placed in the freeze drier.
Operation of the freeze drying process then produces solid sodium amoxycillin already in place in glass vials which may then be sealed. Such process is simple and convenient.
The preceding process may easily be carried out under sterile conditions.
The solid produced by the freeze drying process of this invention appears to he particularly stable when it contains about 0.5- 10% w/w of a secondary or tertiary carbinol, of 4 or 5 carbon atoas especially when it is tert-bircanol.
The preceding powders may be dissolved in sterile water to provide an injectable composition of sodium amoxycillin, for human or veteranary use.
From the foregoing it will be realized that a preferred aspect of this invention provides a process for the preparation of solid s'iium amoxycillin which process comprises freeze drying a solution of sodium amoxycillin dissolved in a mixture of water and tert-butanol.
A favoured form cf this aspect of the invention comprises freeze drying a solution consisting essentially of 10% w/v to 15% w/v of sodium amoxycillin dissolved in a solvent system consisting essentially of 2% v/v to 30% v/v of aqueous tert-butanol.
A further preferred aspect of this invention consists of solid powder which consists essentially of sodium - 7 amoxycillin and 0.5% w/v tc 6% w/w of tent-butanol ( and up to about 4% by weight water).
This invention also provides an injectable composition which comprises an aqueous solution of sodium amoxycillin which also contains tert-butanol present by from 0.5% to S% of the weight of sodium amoxycillin.
Most suitably such compositions contain no.more· than 4% of the tert-butanol. i0 Those skilled in the art of freeze drying will realise that the solvent used in such processes is almost inevitabl water. Although it is believed that aqueous ethanol has. occasionally been used as a solvent for freeze drying it is believed that, Ί5 prior to the present invention, no public recommendation or use of tert-butanol has occured for preparing antibacterial agents such as a salt of penicillin or cephalosporin.
The following examples illustrate the invention:«5353 Example 1: Preparation of Solid Sodium Amoxycillin Amoxycillin trihydrate (I74g) was suspended in a mixture of tert-butanol (100ml) and water (500ml). The suspension was maintained at 15°C and neutralised to clarity by the addition of sodium hydroxide solution (2N, 250 ml). The resulting clear solution was filtered, made up to 11 with water and cooled to 0°C. The cold solution was metered into glass vials, loaded onto the pre-cooled shelves of a freeze dryer, frozen and dried by the following cycle; Freezing - 45°C with vacuum - 45°C to + 40°C 40°C hours 0-4 hours 4-38 hours 33 - 42 hours The resulting material assayed as containing 1 - 3 % 15 w/w tert-butanol and 1% w/w water in addition to the sodium amoxycillin. -9 453 S3 } Example 2; Demonstration of Improvements (a) The purity of sodium salt produced by Example 1 was compared to that produced by the freeze drying process in · the absence of tert-butanol and when the tert-butanol was '5 replaced by ethanol. The results are given in Table 1.
Table 1: Purity of Product Freeze Drying Solvent .% Purity of Resulting Sodium Amoxycillin (anhydrous basis) Water 85 15% v/v Ethanol/Water 87 25% v/v Tert-butanol/Water 95 (b) The storage stability of the sodium salt produced in Example 1 was compared to that produced by the freeze drying •15 process in which the tert-butanol was replaced by ethanol.
The results are given in Table 2.
Table 2; Stability of Product Freeze Drying Solvent - · % Initial amoxycillin remaining after storage 12 weeks at 45°C 6 months. at room temperature 15% v/v Ethanol/ Water 88 95 ι 10% v/v Tertbutanol/ . Water 93 98 j i - 10 45353 (c) The above data demonstrates that use of freeze drying from an tert-butanol/water solvent system produces a purer, more stable product that does freeze drying from a water or an ethanol/water solvent system. - li 45353 Example 5: Preparation of Bulk Freeze-Dried Sodium Amoxycillin.
To a slurry of Amoxycillin Trihydrate (450 gas. activity) in water 1.7L.) and tert-butanol (0.3L.) at 22°C was added 1.1. equivalents of 2N-sodium hydroxide The resulting clear solution was immediately cooled to 0°C and sterilely-filtered into freeze-drying trays to a depth of 0.95 - 1.0 cm. The trays were then loaded onto the pre-cooled shelves of a freeze-dryer, frozen to -50°C and dried in a manner similar to that described in Example 1. The resulting Sodium Amoxycillin was 94.3% pure (anhydrous basis) and contained 1.2% w/w moisture and 0.9% w/w tert-butanol.

Claims (25)

1. A process for the preparation of solid sodium amoxycillin, which process comprises freeze drying a solution of sodium amoxycillin in a solvent system containing water and at least one secondary or tertiary or carbinol, which is at least 5% v/v soluble in water at 25°C, the secondary or tertiary carbinol being present in the solv .nit system in a proportion of 2% to 60% v/v, or to its maximum miscibility if lower.
2. A process as claimed in claim 1 wherein the solvent system contains at least 2% v/v of carbinol.
3. A precess as claimed in claim 2 wherein the solvent system contains initially from 4% to 50% v/v of carbinol.
4. A process as claimed in claim 3 wherein the solvent system contains initially from 8% to 35% v/v of carbinol.
5. A process as claimed in claim 4 wherein the solvent system contains from 10% to 25% v/v of carbinol.
6. A process as claimed in any one of claims 1 to 5 wherein the carbinol is a tertiary carbinol.
7. A precess as claimed in claim 6 wherein the carbinol is tert-butanol. - 13 • 45353
8. A process as claimed in any one of claims 1 to 7 wherein the concentration of sodium amoxycillin in solution immediately prior to freeze drying is in the range of 8% w/v to 20%w/v. 5
9. A process as claimed in claim 8 wherein the concentration of sodium amoxycillin is in the range 10% w/v to 15% w/v.
10. A process as claimed in claim 9 wherein the concentration of sodium amoxycillin is 12% w/v.
11. A process as claimed in any one o£ claims l to 10 wherein the 10 freeze drying process is carried out at an initial temperature below -25°C,
12. A process as claimed.in claim 11 wherein the initial temperature is below -30¾.
13. A process as claimed in claim 12 wherein the initial 15 temperature is below -35¾.
14. A process as claimed in any one of claims 1 to 13 wherein the initial temperature is allowed to rise gradually such that ns melting occurs to a final drying temperature until no more than 10% by weight of 20 residual solvent remains in the solid product. 14 453S3
15. A process as claimed in any one of claims 1 to 14 wherein the initial temperature is allowed to rise gradually over a period of at least one day to a final drying temperature which is not greater than 60°C such that no more than 10%· by weight of residual solvent remains in the solid product.
16. A process as claimed in c.laim 15 wherein the final drying temperature is not greater than 50°C.
17. A process as claimed in any one of claims 1 to 16 wherein the product contains net more than 6% w/w of residual solvent.
18. A process for the preparation of solid sodium amoxycillin, which process comprises freeze drying a solution consisting essentially of 10% w/v to 15JS w/v _ of sodium amoxycillin dissolved in 2% v/v to 30% v/v cf aqueous tert-butancl.
19. A process as claimed in any one of claims 1 to 18 wherein the solvents are pyrogen free.
20. A process as claimed in any one of claims 1 to 19, substantially as described herein with reference to the Example 3.
21. Solid sodium amoxycillin prepared by any one of the processes of claim 1 to 19 containing 0.5 - 10$ w/w of a secondary or tertiary carbinol of 4 or 5 carbon atoms. - 15. ' 45353
22. Sodium amoxycillin as claimed in claim 21 wherein the carbinol is tert-butanol.
23. Solid sodium amoxycillin prepared, by any one of the process of claims 1 to 19 containing from 0,5 to 6% w/w 5 of tert-butanol and up to 4% by weight water >
24. Sodium amoxycillin whenever prepared by the process as claimed in any one of claims 1 to 20.
25. A pharmaceutical composition adapted for administration by injection, comprising an aqueous solution of sodium 10 amoxycillin as claimed in any one of claims 21 to 24 and a pharmaceutically acceptable carrier.
IE1399/77A 1976-07-07 1977-07-06 A procress for preparing solid sodium amoxycillin IE45353B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB28179/76A GB1527557A (en) 1976-07-07 1976-07-07 Process for preparing solid sodium amoxycillin

Publications (2)

Publication Number Publication Date
IE45353L IE45353L (en) 1978-01-07
IE45353B1 true IE45353B1 (en) 1982-08-11

Family

ID=10271535

Family Applications (1)

Application Number Title Priority Date Filing Date
IE1399/77A IE45353B1 (en) 1976-07-07 1977-07-06 A procress for preparing solid sodium amoxycillin

Country Status (6)

Country Link
DK (1) DK144273C (en)
ES (1) ES460437A1 (en)
IE (1) IE45353B1 (en)
IL (1) IL52350A (en)
SE (1) SE432933B (en)
ZA (1) ZA773706B (en)

Also Published As

Publication number Publication date
DK144273B (en) 1982-02-01
ZA773706B (en) 1978-06-28
IE45353L (en) 1978-01-07
SE432933B (en) 1984-04-30
SE7707836L (en) 1978-01-08
IL52350A (en) 1979-11-30
DK305877A (en) 1978-01-08
IL52350A0 (en) 1977-08-31
DK144273C (en) 1982-07-12
ES460437A1 (en) 1978-10-01

Similar Documents

Publication Publication Date Title
JP3576180B2 (en) Improved ifosfamide lyophilized composition
US4104391A (en) Method of preparing stable sterile ampoules of crystalline cephalosporins for parenteral administration
CA1056729A (en) Injectable amoxycillin composition
US4146971A (en) Method of preparing a rapidly dissolving powder of sterile crystalline cefazolin sodium for parenteral administration
RU2205012C2 (en) Pharmaceutical compositions for drying by freezing
US4222939A (en) Process for preparing solid sodium amoxycillin
KR900003491B1 (en) Lyophilized composition containing isofamide and process for its preparation
US4303582A (en) Spray drying process for preparation of solid sodium amoxycillin
CS214798B2 (en) Method of stabilization of active substances
US5972912A (en) Method for lyophilizing ifosfamide
IE45353B1 (en) A procress for preparing solid sodium amoxycillin
US4002748A (en) Method of preparing sterile essentially amorphous cefazolin for reconstitution for parenteral administration
CZ293433B6 (en) Lyophilized thioxanthenone antitumor agents
US4132848A (en) Method of preparing a rapidly dissolving powder of crystalline cephalothin sodium for parenteral administration
EP0012496B1 (en) A process for the preparation of a solid sodium amoxycillin and aqueous solutions thereof
JP2988631B2 (en) Lyophilized preparation of fosfomycin sodium and method for producing the same
EP1534721B1 (en) Process for controlling the hydrate mix of the disodium salt of fosfluconazole
JPS6019759B2 (en) For parenteral administration 11115152139199 2-3-13 Kyobashi, Chuo-ku, Tokyo
RU2659160C1 (en) Bortezomib lyophilizate production method and the bortezomib containing pharmaceutical composition in the form of stable lyophilizated product produced by said method
JPS61130223A (en) Freeze-dried antibacterial preparation
US3734902A (en) Highly soluble glucoside compositions and method of preparing same
US20040007689A1 (en) Process for controlling the hydrate mix of a compound
CZ279454B6 (en) Process for preparing dry injections of cis-diaminedichloroplatinum complex
IE45995B1 (en) Improvements in or relating to freeze drying cephalothin sodium
WO1994008592A1 (en) Lyophilized cyclophosphamide compositions